• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Gut microbiota dynamics and uraemic toxins: one size does not fit all.

作者信息

Joossens Marie, Faust Karoline, Gryp Tessa, Nguyen Anh Thi Loan, Wang Jun, Eloot Sunny, Schepers Eva, Dhondt Annemieke, Pletinck Anneleen, Vieira-Silva Sara, Falony Gwen, Vaneechoutte Mario, Vanholder Raymond, Van Biesen Wim, Huys Geert Roger Bertrand, Raes Jeroen, Glorieux Griet

机构信息

Laboratory of Molecular Bacteriology- Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.

Center for Microbiology, VIB, Leuven, Belgium.

出版信息

Gut. 2019 Dec;68(12):2257-2260. doi: 10.1136/gutjnl-2018-317561. Epub 2018 Nov 21.

DOI:10.1136/gutjnl-2018-317561
PMID:30464044
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6872439/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7428/6872439/ff9ffa005365/gutjnl-2018-317561f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7428/6872439/17337b07844c/gutjnl-2018-317561f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7428/6872439/ff9ffa005365/gutjnl-2018-317561f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7428/6872439/17337b07844c/gutjnl-2018-317561f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7428/6872439/ff9ffa005365/gutjnl-2018-317561f02.jpg

相似文献

1
Gut microbiota dynamics and uraemic toxins: one size does not fit all.肠道微生物群动态变化与尿毒症毒素：一刀切并不适用。
Gut. 2019 Dec;68(12):2257-2260. doi: 10.1136/gutjnl-2018-317561. Epub 2018 Nov 21.
2
Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease.肠道激素、肠道微生物群与非酒精性脂肪性肝病
Minerva Endocrinol. 2017 Jun;42(2):184-194. doi: 10.23736/S0391-1977.16.02567-0. Epub 2016 Nov 23.
3
Gut microbiota and non-alcoholic fatty liver disease.肠道微生物群与非酒精性脂肪性肝病
Hepatobiliary Pancreat Dis Int. 2015 Dec;14(6):572-81. doi: 10.1016/s1499-3872(15)60026-1.
4
The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation.非酒精性脂肪性肝病的肠道微生物群：当前方法及其解读
Hepatol Int. 2015 Jul;9(3):406-15. doi: 10.1007/s12072-015-9640-2. Epub 2015 Jun 12.
5
Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.甘草酸二铵通过调节肠道菌群和恢复肠道屏障保护小鼠非酒精性脂肪性肝病。
Mol Pharm. 2018 Sep 4;15(9):3860-3870. doi: 10.1021/acs.molpharmaceut.8b00347. Epub 2018 Aug 2.
6
Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier.丁酸钠通过改善肠道微生物群和胃肠道屏障减轻高脂饮食诱导的小鼠脂肪性肝炎。
World J Gastroenterol. 2017 Jan 7;23(1):60-75. doi: 10.3748/wjg.v23.i1.60.
7
The role of the gastrointestinal tract and microbiota on uremic toxins and chronic kidney disease development.胃肠道和微生物群在尿毒症毒素及慢性肾脏病发展中的作用
Clin Exp Nephrol. 2017 Feb;21(1):7-15. doi: 10.1007/s10157-016-1255-y. Epub 2016 Mar 10.
8
Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice.肠道微生物群移植、槲皮素与高脂饮食之间的功能相互作用决定无菌小鼠非酒精性脂肪性肝病的发生。
Mol Nutr Food Res. 2019 Apr;63(8):e1800930. doi: 10.1002/mnfr.201800930. Epub 2019 Feb 4.
9
[Gut microbiota and kidney diseases : dangerous liaisons?].[肠道微生物群与肾脏疾病：危险关系？]
Rev Med Suisse. 2018 Feb 21;14(595):422-425.
10
Emodin via colonic irrigation modulates gut microbiota and reduces uremic toxins in rats with chronic kidney disease.大黄素通过结肠灌洗调节慢性肾脏病大鼠的肠道微生物群并降低尿毒症毒素。
Oncotarget. 2016 Apr 5;7(14):17468-78. doi: 10.18632/oncotarget.8160.

引用本文的文献

1
A specifically designed multi-biotic reduces uremic toxin generation and improves kidney function.一种专门设计的多种生物制剂可减少尿毒症毒素的产生并改善肾功能。
Gut Microbes. 2025 Dec;17(1):2531202. doi: 10.1080/19490976.2025.2531202. Epub 2025 Jul 12.
2
Pediatric and adult point of view on the gut-kidney axis in CKD.儿童和成人对慢性肾脏病中肠-肾轴的观点。
Pediatr Nephrol. 2025 Jul 7. doi: 10.1007/s00467-025-06780-8.
3
A bibliometric study of global trends in diabetic nephropathy and intestinal flora research.糖尿病肾病与肠道菌群研究全球趋势的文献计量学分析

本文引用的文献

1
Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.小代谢物，大变化：以微生物组为中心的非酒精性脂肪性肝病观。
Gut. 2019 Feb;68(2):359-370. doi: 10.1136/gutjnl-2018-316307. Epub 2018 Aug 31.
2
Gut-Derived Metabolites and Chronic Kidney Disease: The Forest (F)or the Trees?肠道衍生代谢产物与慢性肾脏病：见林还是见树？
Clin J Am Soc Nephrol. 2018 Sep 7;13(9):1311-1313. doi: 10.2215/CJN.08200718. Epub 2018 Aug 7.
3
Spontaneous variability of pre-dialysis concentrations of uremic toxins over time in stable hemodialysis patients.
Front Microbiol. 2025 May 21;16:1577703. doi: 10.3389/fmicb.2025.1577703. eCollection 2025.
4
Regulation of the blood-brain barrier function by peripheral cues in health and disease.健康与疾病状态下外周信号对血脑屏障功能的调节
Metab Brain Dis. 2024 Dec 13;40(1):61. doi: 10.1007/s11011-024-01468-8.
5
Future of Uremic Toxin Management.尿毒症毒素管理的未来。
Toxins (Basel). 2024 Oct 28;16(11):463. doi: 10.3390/toxins16110463.
6
The effect of synbiotic supplementation on plasma levels of advanced glycation end products and cardiovascular risk factors in hemodialysis patients: A double-blind clinical trial.合生制剂补充对血液透析患者血浆晚期糖基化终产物水平及心血管危险因素的影响：一项双盲临床试验。
Food Sci Nutr. 2024 Jul 12;12(9):6864-6872. doi: 10.1002/fsn3.4338. eCollection 2024 Sep.
7
Clinical Perspectives of Gut Microbiota in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: Where Do We Stand?慢性肾脏病和终末期肾病患者肠道微生物群的临床视角：我们目前的进展如何？
Biomedicines. 2023 Sep 7;11(9):2480. doi: 10.3390/biomedicines11092480.
8
Underdevelopment of gut microbiota in failure to thrive infants of up to 12 months of age.12 月龄以下生长迟缓婴儿肠道微生物群发育不良。
Front Cell Infect Microbiol. 2022 Dec 12;12:1049201. doi: 10.3389/fcimb.2022.1049201. eCollection 2022.
9
A novel therapeutic concern: Antibiotic resistance genes in common chronic diseases.一个新的治疗关注点：常见慢性病中的抗生素耐药基因。
Front Microbiol. 2022 Oct 17;13:1037389. doi: 10.3389/fmicb.2022.1037389. eCollection 2022.
10
Enterorenal crosstalks in diabetic nephropathy and novel therapeutics targeting the gut microbiota.糖尿病肾病中的肠-肾相互作用及靶向肠道微生物群的新型治疗方法。
Acta Biochim Biophys Sin (Shanghai). 2022 Oct 25;54(10):1406-1420. doi: 10.3724/abbs.2022140.
稳定血液透析患者透析前尿毒症毒素浓度随时间的自发变异性。
PLoS One. 2017 Oct 10;12(10):e0186010. doi: 10.1371/journal.pone.0186010. eCollection 2017.
4
Population-level analysis of gut microbiome variation.人群水平的肠道微生物组变异分析。
Science. 2016 Apr 29;352(6285):560-4. doi: 10.1126/science.aad3503. Epub 2016 Apr 28.
5
Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial.合生元通过改善肠道微生物群缓解肾衰竭（SYNERGY）：一项随机试验
Clin J Am Soc Nephrol. 2016 Feb 5;11(2):223-31. doi: 10.2215/CJN.05240515. Epub 2016 Jan 15.
6
The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease.肠道微生物群、肠漏和肾脏疾病中的异常免疫。
Kidney Int. 2013 Jun;83(6):1010-6. doi: 10.1038/ki.2012.440. Epub 2013 Jan 16.
7
Chronic kidney disease alters intestinal microbial flora.慢性肾脏病改变肠道微生物菌群。
Kidney Int. 2013 Feb;83(2):308-15. doi: 10.1038/ki.2012.345. Epub 2012 Sep 19.
8
Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients.血清吲哚硫酸酯与慢性肾脏病患者的血管疾病和死亡率相关。
Clin J Am Soc Nephrol. 2009 Oct;4(10):1551-8. doi: 10.2215/CJN.03980609. Epub 2009 Aug 20.
9
p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin.在血液透析患者中，血清中对羟苯磺酸的浓度可通过富含低聚果糖的菊粉这种益生原来降低。
Nephrol Dial Transplant. 2010 Jan;25(1):219-24. doi: 10.1093/ndt/gfp414. Epub 2009 Aug 19.
10
Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis.对接受血液透析的尿毒症患者口服乳酸菌制剂Lebenin后，其血液中尿毒症毒素及其粪便中前体物质的蓄积的抑制作用。
Nephron. 1996;74(2):349-55. doi: 10.1159/000189334.